Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany flag Germany · Delayed Price · Currency is EUR
0.2400
+0.0400 (20.00%)
At close: Jul 23, 2025

Northwest Biotherapeutics Company Description

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer.

The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.

The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers.

Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Northwest Biotherapeutics, Inc.
CountryUnited States
Founded1996
IndustryBiological Products, Except Diagnostic Substances
Employees25
CEOLinda Powers

Contact Details

Address:
4800 Montgomery Lane
Bethesda, Delaware 20814
United States
Phone240 497 9024
Websitenwbio.com

Stock Details

Ticker SymbolNBYB
ExchangeStuttgart Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
Linda PowersChief Executive Officer
Linda PowersChief Financial Officer
David InnesHead of Investor Relations